Evidence map›Paper›PMID 42482255›Full record

ArticleOrphanet journal of rare diseases2026

Launching a multi-level data strategy for rare eye diseases: a methodological case study from national to European scale.

Camille Beluffi-Marin, Marilyne Oswald, Isabella Anna Vacchi, David Keegan, Bart Peter Leroy, Hélène Dollfus

Abstract read
PubMed Publisher
In one paragraph

Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Camille Beluffi-MarinLaboratoire de Génétique Médicale, UMR_S INSERM U1112, IGMA (Institut de Génétique Médicale d'Alsace), Université de Strasbourg, Strasbourg, France. beluffi@unistra.fr.ORCID http://orcid.org/0009-0007-3391-6604
Marilyne OswaldFSMR SENSGENE Management Team, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Isabella Anna VacchiERN-EYE Coordination Center, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
David KeeganDepartment of Ophthalmology, Mater Misericordiae University Hospital, Dublin, Ireland.
Bart Peter LeroyDepartment of Ophthalmology, Ghent University Hospital, Ghent, Belgium.
Hélène DollfusLaboratoire de Génétique Médicale, UMR_S INSERM U1112, IGMA (Institut de Génétique Médicale d'Alsace), Université de Strasbourg, Strasbourg, France.

Funding

Agence Nationale de la Recherche ANR-21-PMRB-0009Fund for Scientific Research (Flandres) Fund for Scientific Research (Flandres)health program of the european union 739534 'ERN-EYE'Ministère de l'Economie, du Redressement Productif et du Numérique Ministère de l'Economie, du Redressement Productif et du Numérique
6 · The paper itself

Abstract

Rare eye diseases bring unique challenges in clinical research and patient care due to their heterogeneity, low prevalence, and dispersed expertise. To address these challenges, an integrated multilevel data strategy has been developed in France and Europe, enabling structured, interoperable data collection and reuse across national and transnational initiatives. In this paper, we present a methodological framework using the metaphor of a spaceship to illustrate the vertical articulation of this ecosystem, from national infrastructures to European platforms. At the base of the spaceship lies BaMaRa, France's national registry for rare diseases, which ensures the systematic collection of core clinical data at the point of care. The next stage is FREDD, a disease-specific data warehouse dedicated to rare eye conditions, developed by the SENSGENE network thanks to the France 2030 RaReTiA project. FREDD integrates granular phenotypic and genotypic data, allowing for in-depth research and cohort building. FREDD is fully interoperable with BaMaRa, ensuring data consistency and minimizing redundancies. The third level of the spaceship is REDgistry, the European registry for rare eye diseases coordinated by ERN-EYE. REDgistry allows for cross-border data harmonization and aligns with FAIR principles to facilitate data sharing and secondary use in international research. At the top of the structure is the European Health Data Space, a future platform enabling secure and standardized access to health data for research and policy-making at the EU level. At the core of this architecture remains the patient, whose data is the very foundation of the system. Although not always actively involved in data collection, the patient remains central to the purpose and structure of each data layer. Building and sustaining such a complex infrastructure requires the coordination of a wide range of stakeholders, including clinicians, research networks, data stewards, hospital IT departments, national authorities, and European institutions. The success of this multilevel model depends on shared standards, transparent governance, and sustained collaboration across all actors. Together, they form the propulsion system of the spaceship, enabling the structured reuse of high-quality data to accelerate research and improve care in the field of rare eye diseases.

Indexed as

Eye DiseasesRare DiseasesEuropeFranceHumansRegistriesBaMaRaBNDMRData governanceERN-EYEHealth care data secondary useHealth data warehouseInteroperabilityRare eye diseasesSENSGENE

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.